Literature DB >> 26309587

Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer.

Hengli Dou1, Yan Wang2, Gang Su3, Song Zhao1.   

Abstract

BACKGROUND: Non-small-cell lung cancer (NSCLC) is one of the leading causes of death. The aim of the present study was to compare the expression of let-7c and miR-152 in surgically resected NSCLC cases and healthy cases to evaluate their diagnostic impact.
METHODS: This hospital-based case-control study included 120 NSCLC patients and 360 healthy controls. The miRNA levels were measured via quantitative reverse transcription-polymerase chain reaction and their association with NSCLC was assessed by statistical data analysis and receiver operating characteristic curves.
RESULTS: The expression of let-7c and miR-152 in plasma were found to be downregulated in the patients with NSCLC. Advanced studies showed that the plasma let-7c and miR-152 were correlated with the clinicopathological features such as histological classifications, differentiation status, lymph node metastasis and stage classifications. The ROC curves for the miRNAs revealed a strong diagnostic performance. ROC curve analyses revealed that both plasma let-7c and miR-152 could serve as valuable biomarkers for NSCLC cases from healthy controls with an AUC of 0.714 and 0.845.
CONCLUSION: It was found that let-7c and miR-152 are significantly reduced in plasma samples of NSCLC patients. These findings suggest that detection of circulating let-7c and miR-152 can be developed into a noninvasive and rapid diagnostic tool for the individuals with NSCLC.

Entities:  

Keywords:  biomarker; diagnosis; miRNA; non-small-cell lung cancer

Year:  2015        PMID: 26309587      PMCID: PMC4538081     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  24 in total

1.  CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes.

Authors:  Oksana Kowalczuk; Tomasz Burzykowski; Wieslawa Ewa Niklinska; Miroslaw Kozlowski; Lech Chyczewski; Jacek Niklinski
Journal:  Tumour Biol       Date:  2014-02-06

2.  Epithelial and stromal expression of miRNAs during prostate cancer progression.

Authors:  Qinghu Ren; Jiaqian Liang; Jianjun Wei; Olca Basturk; Jinhua Wang; Garrett Daniels; Lan Lin Gellert; Yirong Li; Ying Shen; Iman Osman; Jun Zhao; Jonathan Melamed; Peng Lee
Journal:  Am J Transl Res       Date:  2014-07-18       Impact factor: 4.060

3.  Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1.

Authors:  Jinfeng Huang; Yue Wang; Yingjun Guo; Shuhan Sun
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

4.  MicroRNA-152 targets ADAM17 to suppress NSCLC progression.

Authors:  Yunshu Su; Yuchang Wang; Hongmin Zhou; Lei Lei; Lijun Xu
Journal:  FEBS Lett       Date:  2014-04-26       Impact factor: 4.124

5.  Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.

Authors:  Yiwei Li; Timothy G VandenBoom; Dejuan Kong; Zhiwei Wang; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

6.  Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse.

Authors:  Sumithra J Mandrekar; Ming-Wen An; Jeffrey Meyers; Axel Grothey; Jan Bogaerts; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

7.  MicroRNA-152 targets DNA methyltransferase 1 in NiS-transformed cells via a feedback mechanism.

Authors:  Weidong Ji; Lei Yang; Jianhui Yuan; Linqing Yang; Mei Zhang; Defeng Qi; Xiaolu Duan; Aiguo Xuan; Wenjuan Zhang; Jiachun Lu; Zhixiong Zhuang; Guohua Zeng
Journal:  Carcinogenesis       Date:  2012-11-03       Impact factor: 4.944

8.  Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.

Authors:  Maria Schubert; Martin Spahn; Susanne Kneitz; Claus Jürgen Scholz; Steven Joniau; Philipp Stroebel; Hubertus Riedmiller; Burkhard Kneitz
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

9.  Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells.

Authors:  Wanzhong Yin; Ping Wang; Xin Wang; Wenzhi Song; Xiangyan Cui; Hong Yu; Wei Zhu
Journal:  Braz J Med Biol Res       Date:  2013-06-12       Impact factor: 2.590

10.  Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device.

Authors:  Andrew C Morley-Smith; Adam Mills; Steven Jacobs; Bart Meyns; Filip Rega; André R Simon; John R Pepper; Alexander R Lyon; Thomas Thum
Journal:  Eur J Heart Fail       Date:  2014-06-24       Impact factor: 15.534

View more
  21 in total

Review 1.  Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

2.  miR-152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer.

Authors:  Dongmei Yang; Qiumei Zhang
Journal:  Oncol Lett       Date:  2019-04-09       Impact factor: 2.967

3.  Upregulation of microRNA-18b induces phosphatase and tensin homolog to accelerate the migration and invasion abilities of ovarian cancer.

Authors:  Xiaofang Han; Yan Zhang; Dong Wang; Xinyun Fu; Meiqing Li; Aiming Wang
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

4.  MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.

Authors:  Wen Qin; Wei Xie; Qinglin He; Tianwei Sun; Chaoguo Meng; Kunling Yang; Yuanfu Luo; Dongmei Yang
Journal:  Exp Ther Med       Date:  2017-11-17       Impact factor: 2.447

Review 5.  Clinical significance of circulating miRNA detection in lung cancer.

Authors:  Chen Zhao; Funian Lu; Hongxia Chen; Fuqiang Zhao; Ziwen Zhu; Xianda Zhao; Honglei Chen
Journal:  Med Oncol       Date:  2016-03-31       Impact factor: 3.064

Review 6.  MicroRNAs: A novel potential biomarker for diagnosis and therapy in patients with non-small cell lung cancer.

Authors:  Qun Zhou; Shao-Xin Huang; Feng Zhang; Shu-Jun Li; Cong Liu; Yong-Yong Xi; Liang Wang; Xin Wang; Qi-Qiang He; Cheng-Cao Sun; De-Jia Li
Journal:  Cell Prolif       Date:  2017-10-08       Impact factor: 6.831

Review 7.  Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC.

Authors:  Jinpao Hou; Fei Meng; Lawrence W C Chan; William C S Cho; S C Cesar Wong
Journal:  Front Genet       Date:  2016-11-03       Impact factor: 4.599

8.  Identification of A Panel of Serum microRNAs as Biomarkers for Early Detection of Lung Adenocarcinoma.

Authors:  Shaogang Lv; Jian Xue; Chuanyong Wu; Lin Wang; Jing Wu; Shujun Xu; Xiaohui Liang; Jiatao Lou
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

9.  The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers.

Authors:  Yanlong Yang; Zaoxiu Hu; Yongchun Zhou; Guangqiang Zhao; Yujie Lei; Guangjian Li; Shuai Chen; Kai Chen; Zhenghai Shen; Xiao Chen; Peilin Dai; Yunchao Huang
Journal:  Oncotarget       Date:  2017-10-04

Review 10.  New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.

Authors:  Erika Larrea; Carla Sole; Lorea Manterola; Ibai Goicoechea; María Armesto; María Arestin; María M Caffarel; Angela M Araujo; María Araiz; Marta Fernandez-Mercado; Charles H Lawrie
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.